Sens. Burr and Coburn Want User Fee Bills That Streamline Regulation
Executive Summary
Two senators have picked up the banner advocating for improved regulatory timeliness and certainty through the user fee programs, but broadcast the message to the industry trade groups most certainly in favor of the ideas.
You may also be interested in...
Burr Warns User Fee Renewal Could Be Difficult Without Performance Measure Improvements
Senator tells FDA Commissioner Hamburg that time to market is important metric during hearing dominated by questions about medical device review.
Not Another FDAAA – Observers Expect Fewer FDA Reforms In PDUFA V
Congress is not expected to pile as many new responsibilities on FDA in the upcoming Prescription Drug User Fee Act reauthorization as in 2007’s FDA Amendments Act.
Not Another FDAAA – Observers Expect Fewer FDA Reforms In PDUFA V
Congress is not expected to pile as many new responsibilities on FDA in the upcoming Prescription Drug User Fee Act reauthorization as in 2007’s FDA Amendments Act.